OMVAX INC
Next-generation meningococcal vaccines for all ages
San Francisco, United States · Founded 2016
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2016
- Business Model
- B2B
- Website
- craft.co
About
OMVax is a San Francisco-based biotechnology company developing next-generation meningococcal group B (MenB) vaccines based on native outer membrane vesicles (NOMVs). Their combination vaccine targets Neisseria meningitidis and Neisseria gonorrhoeae strains and is designed for use across age groups including infants and young children. The company has received NIH SBIR funding and collaborates with academic institutions for vaccine research.
Summary
OMVAX INC is a Biotech company based in San Francisco, United States, founded in 2016.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/omvax-inc"><img src="https://indexed.vc/api/badge/company/omvax-inc" alt="OMVAX INC on Indexed.vc" width="260" height="76" /></a>